A project led by Jonathan Rossiter, Professor of Robotics at the University of Bristol, UK is set to explore how artificial muscles could radically transform treatment options and effectively turn back the body clock.
Sarcopenia is responsible for a large number of health problems and body function disorders, and is brought about by ageing, stroke, trauma and degenerative diseases. Current treatments are predominantly based on external devices such as orthoses and rigid exoskeletons, but these can cause tissue damage and are limited in use.
“We are working on the principle that implanting robotic, artificial muscles to replace or work alongside our own muscles, can restore natural body function and help us all to live longer, more comfortable and active lives,” said Professor Rossiter.
The project, called emPOWER, is led by Professor Rossiter in partnership with Imperial College, UCL and the NIHR Devices for Dignity MedTech Co-operative, hosted by Sheffield Teaching Hospitals Foundation Trust.
“emPOWER implantable muscles must work seamlessly with the body,” continued Professor Rossiter. “They must be biocompatible, integrate smoothly and strongly with natural bone and tissue, and coordinate intelligently with the patient’s own movements and muscle actions.”
To deliver this level of sophistication, the emPOWER project consists of a multi-disciplinary team of 30 researchers across the fields of soft robotics, materials science, bioengineering, chemistry, ethics, healthcare regulation and medicine.
“Together the emPOWER team will deliver a system of implantable muscles that receive their energy from outside the body, for example from a small power pack, and which communicate directly with the nervous system for control and sensing,” said Professor Rossiter. “There is considerable work to be done but we confidently expect to see emPOWER artificial muscles in clinical use before 2050.”
The project is funded by the Engineering and Physical Sciences Research Council (EPSRC), part of UK Research and Innovation, through its Transformative Healthcare Technologies for 2050.